Who are TISSEEL Lyo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fibrin Sealant (Artiss), TachoSil, Tisseel Fibrin Sealant, Bioseal Fibrin Sealant, TISSEEL VH fibrin sealant, Fibrin sealant hemipelvis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tisseel-lyo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

TISSEEL Lyo — Competitive Intelligence Brief

TISSEEL Lyo (TISSEEL Lyo) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrin sealant. Area: Surgical Hemostasis.

phase 3 Fibrin sealant Surgical Hemostasis Biologic Live · refreshed every 30 min

Target snapshot

TISSEEL Lyo (TISSEEL Lyo) — Baxter Healthcare Corporation. TISSEEL Lyo is a fibrin sealant used to control bleeding.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TISSEEL Lyo TARGET	TISSEEL Lyo	Baxter Healthcare Corporation	phase 3	Fibrin sealant
Fibrin Sealant (Artiss)	Fibrin Sealant (Artiss)	Nguyen, Davis B., M.D.	marketed	Fibrin sealant	Fibrinogen; thrombin substrate
TachoSil	TachoSil	GATT Technologies BV	marketed	Hemostatic agent / Fibrin sealant	Fibrinogen (conversion to fibrin via thrombin)
Tisseel Fibrin Sealant	Tisseel Fibrin Sealant	Massachusetts General Hospital	marketed	Fibrin sealant	Fibrinogen (substrate for thrombin-catalyzed polymerization)
Bioseal Fibrin Sealant	Bioseal Fibrin Sealant	Ethicon, Inc.	marketed	Fibrin sealant / Hemostatic agent
TISSEEL VH fibrin sealant	TISSEEL VH fibrin sealant	Baxter Healthcare Corporation	phase 3	Fibrin sealant	Fibrinogen; Thrombin substrate
Fibrin sealant hemipelvis	Fibrin sealant hemipelvis	IBON JAUNARENA	phase 3	Hemostatic agent / Fibrin sealant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrin sealant class)

Baxter Healthcare Corporation · 2 drugs in this class
Massachusetts General Hospital · 1 drug in this class
Nguyen, Davis B., M.D. · 1 drug in this class
Nycomed · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TISSEEL Lyo — Competitive Intelligence Brief. https://druglandscape.com/ci/tisseel-lyo. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab